NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Cover of LiverTox

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Show details


Last Update: October 17, 2017.



Clonidine is a centrally active alpha-adrenergic agonist used predominantly as an antihypertensive agent, usually in combination with other agents. Despite wide scale use for many years, clonidine has not been linked definitively to either serum aminotransferase elevations or clinically apparent liver injury.


Clonidine (klon' i deen) is an antihypertensive agent which acts by stimulation of the alpha 2A subtype of alpha adrenergic receptors in the brainstem, causing a reduction in the sympathic outflow of the central nervous system. Decreases in plasma levels of norepinephrine correlate closely with its antihypertensive effects. Clonidine is effective in lowering blood pressure and can be used alone or in combination with other antihypertensive medications. Clonidine is also used in several other conditions in which central nervous system sympathetic activity is believed to contribute including neuropathy, smoking and alcohol cessation, attention deficit disorder, vascular headache, menopausal symptoms, diabetic diarrhea, and restless leg syndrome. Clonidine was approved for use in the United States in 1974 and continues to be widely used with more than 11 million prescriptions being filled yearly. Current approved indications are for treatment of hypertension, but some preparations are also approved for cancer pain management and treatment of attention deficit disorder. Off label uses include treatment of Tourette syndrome, migraine headahces, stress and sleep disorders, and to alleviate symptoms of alcohol, nicotine or narcotic withdrawal. Clonidine is available in tablets of 0.1, 0.2 and 0.3 mg generically and under the brand name of Catapres. Clonidine is also available in fixed combination with diuretics, as a solution for injection and in a transdermal formulation for application once weekly. The typical maintenance dose of clonidine in adults is 0.1 to 0.6 mg daily in 2 to 3 divided doses. Side effects are usually mild and include sedation, fatigue, bradycardia, dry mouth, headaches, dizziness, postural hypotension, male impotence and gastrointestinal upset. Sudden withdrawal can cause rebound hypertension.


Serum aminotransferase elevations during clonidine therapy are uncommon and rates of such elevations have not been reported in the large clinical trials, demonstrating its efficacy in hypertension. Despite many decades of use, clonidine has not been implicated in instances of clinically apparent acute liver injury.

Likelihood score: E (unlikely cause of clinically apparent liver injury).

Mechanism of Injury

Clonidine is metabolized by the cytochrome P450 (CYP) system to a major degree but is typically administered in very low doses (less than 1 mg daily) and neither induces or inhibits CYP activity, which may account in part for its relative lack of hepatotoxicity.

Drug Class: Antihypertensive Agents



Clonidine – Generic, Catapres®


Antihypertensive Agents


Product labeling at DailyMed, National Library of Medicine, NIH


Clonidine Chemical Structure


References updated: 17 October 2017

  • Zimmerman HJ. Drugs used in cardiovascular disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 639-71.
    (Expert review of hepatotoxicity published in 1999; clonidine is not discussed).
  • Bhardwaj SS, Chalasani NP. Antihypertensive agents: Hepatotoxicity of cardiovascular and antidiabetic medications. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 2nd ed. New York: Informa Healthcare USA, 2007, pp. 603.
    (Review of hepatotoxicity of hypertensive agents published in 2007; “clonidine does not seem to cause hepatotoxicity”).
  • Michel T, Hoffman BB. Therapy of myocardial ischemia and hypertension. In, Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 745-88.
    (Textbook of pharmacology and therapeutics; clonidine, guanabenz, and guanfacine stimulate the alpha 2A subtype of the alpha adrenergic receptors in the brainstem and result in reduction in sympathetic outflow from the CNS).
  • Ferder L, Inserra F, Medina F. Safety aspects of long-term antihypertensive therapy(10 years) with clonidine. J Cardiovasc Pharmacol 1987; 10 Suppl 12: S104-8. [PubMed: 2455159]
    (Among 128 patients with hypertension treated with clonidine for up to 10 years, common side effects were drowsiness, dry mouth, constipation, dizziness, postural hypotension and male impotence; there were no significant changes in ALT, AST or Alk P and no discontinuations for liver test abnormalities).
  • Berg PA. [Clonidine therapy as cause of visceral lupus erythematosus?]. Dtsch Med Wochenschr 1993; 118: 1339-40. German. [PubMed: 8375310]
    (83 year old woman on long term clonidine for hypertension and recent addition of enalapril and HCTZ developed fatigue, dry mouth and elevated Alk P and ANA positivity [few details given], which was interpreted as possibly due to clonidine).
  • Heilmann G, Hien P. [Clonidine therapy as cause of lupus erythematosus]. Dtsch Med Wochenschr 1994; 119: 858-9. German. [PubMed: 8005062]
    (Discussion of the likelihood that ACE inhibitors rather than clonidine were the cause of a lupus-like syndrome with hepatotoxicity discussed by Berg [1993]).
  • Drugs for hypertension. Treat Guidel Med Lett 2009; 7: 1-10. [PubMed: 19107095]
    (Brief overview of currently available drugs for hypertension with guidelines on their use and information on prices and toxicities; “Drugs such as clonidine, guanabenz, guanfacine and methyldopa decrease sympathetic outflow… and frequently cause sedation, dry mouth and erectile dysfunction”).
  • Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7. [PMC free article: PMC4446235] [PubMed: 25754159]
    (Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 39 cases [4%] were due to antihypertensive medications, but none to clonidine).
  • Drugs for hypertension. Med Lett Drugs Ther 2017; 59 (1516): 41-8. [PubMed: 28263286]
    (Brief overview of currently available drugs for hypertension with guidelines on their use and information on prices and toxicities; clonidine is listed as a central alpha-adrenergic agonist whose most frequent side effects are dry mouth, sedation, heart block, bradycardia and rebound hypertension; no mention of ALT elevations or hepatotoxicity).


Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...